HAIKOU CITY, Hainan Province, China, Oct. 27 /Xinhua-PRNewswire/ -- China Pharma Holdings, Inc. (''China Pharma’’) today announced it has received the Good Manufacturing Practice (GMP) certification and approval from the Chinese State Food and Drug Administration (SFDA) for the production of cephalosporin.
China Pharma has recently completed its facility dedicated to the production of cephalosporin in the tablet and capsule form. The facility was constructed with advanced computer-controlled manufacturing equipment, which provides increased manufacturing efficiencies and reduces production cost. The new facility can produce up to 250 million tablets and 180 million capsules. Cephalosporin is a class of antibiotics, used in the treatment of infections caused by bacteria. The broad spectrum of activity and safety profile make cephalosporin one of the most widely prescribed class of antimicrobials. In China, antimicrobial sales reach more than $4.8 billion in 2003, according to IMS Health. It is the top selling class of drugs with a growth rate of 20% annually. China Pharma plans to build a separate facility to manufacture the drug in an injectable form.
''We are very pleased that we received the GMP certification for our manufacturing of cephalosporin and the approval from the SFDA for its production. There is a large market opportunity in China for this drug which we feel we are in the position to penetrate,’' commented Zhi-lin Li, President and CEO.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, vascular diseases, CNS and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty bio-pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company’s filings and future filings with the United States Securities and Exchange Commission.
For more information, please contact: Crocker Coulson President CCG Elite Tel: +1-310-231-8600 x103 Email: crocker.coulson@ccgir.com Donald Xu Vice President, Strategic Planning China Pharma Holdings, Inc. Tel: +86-858-776-8880 Email: dxu@chinapharmaholdings.com
China Pharma Holdings, Inc.
CONTACT: Crocker Coulson, President of CCG Elite, +1-310-231-8600 x103, orcrocker.coulson@ccgir.com, for China Pharma Holdings; or Donald Xu, VicePresident, Strategic Planning of China Pharma Holdings, Inc.,+86-858-776-8880, or dxu@chinapharmaholdings.com
